By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Therapeutics 

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: n/a Fax: n/a



Company News
Janssen Therapeutics Release: Your Story, Your HIV Wisdom Brings Together HIV Voices And Supports HIV Community Organizations 9/8/2015 10:16:01 AM
Janssen Therapeutics Submits Supplemental New Drug Application To U.S. FDA For All-Oral, Once-Daily OLYSIO (Simeprevir) In Combination With Sofosbuvir 7/24/2015 7:23:57 AM
Janssen Therapeutics Announces Support For Organizations Focused On Improving Care And Treatment For People Who Inject Drugs Living With HIV And/Or Hepatitis C 4/1/2015 11:30:42 AM
Janssen Therapeutics Release: PREZCOBIX™ (Darunavir/Cobicistat) Approved In The U.S. For The Treatment Of Adults Living With HIV-1 1/30/2015 6:08:55 AM
Johnson & Johnson (JNJ) Announces Collaboration Between Janssen Therapeutics And USAID To Expand Access To Anti-Multidrug-Resistant Tuberculosis (MDR-TB) Compound 12/12/2014 7:39:04 AM
Janssen Therapeutics Announces Recipient of Its Second Point Scholarship for LGBT Students 7/17/2013 8:02:08 AM
Janssen Therapeutics Release: Survey of Participants from Landmark GRACE Trial Provides Patients' Perspectives From an HIV Clinical Study 5/31/2013 9:18:33 AM
Janssen Therapeutics LINCC™ Program Continues Its Commitment to Underserved Populations With Charitable Contributions to 16 HIV/AIDS Organizations Across the U.S. 4/24/2013 10:20:28 AM
Janssen Therapeutics Release: FDA Approves Prescribing Information Update for EDURANT® (Rilpivirine) to Include 96-Week Data in HIV-1-Infected Treatment-Naive Adult Patients 12/11/2012 9:09:14 AM
Janssen Therapeutics's Prezista 800 Mg Tablet Receives FDA Approval 11/12/2012 7:07:49 AM